Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

NCT ID: NCT00126256

Last Updated: 2015-08-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 570 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-02-28
• Study Completion Date: 2006-02-28

Brief Summary

The standard treatment of metastatic colorectal cancer is based on systemic chemotherapy. Several effective drugs are currently available and can be administered either sequentially or in combination. Most patients receive 2 or 3 lines of chemotherapy. The aim of this randomized trial is to evaluate the potential benefit of a bitherapy with 5-fluorouracil (5-FU) and oxaliplatin as first line chemotherapy compared with a sequential chemotherapy with 5-FU alone as first line chemotherapy followed by the combination of 5-FU with oxaliplatin in case of progressive disease, in terms of progression-free survival and overall survival in patients with advanced colorectal cancer.

Detailed Description

Background:

The addition of oxaliplatin and irinotecan to 5-FU improves tumor response rate and progression-free survival in patients with advanced colorectal cancer compared with 5-FU alone, but increases toxicity. It is not clear whether such combination therapies (5-FU+oxaliplatin or 5-FU+irinotecan) should be systematically used as first line treatment or as second line treatment after 5-FU failure.

Design: open-label, multicentric, randomized trial

Aim: The main objective of this multiline strategy trial was to compare two 5-FU based regimens with or without the addition of oxaliplatin to 5-FU in the first line setting in terms of progression-free survival after two lines of chemotherapy in patients with metastatic colorectal cancer.

Treatment compared:

Control arm: first line, 2-hour infusion 400 mg/m² leucovorin (LV) followed by 5-fluorouracil 400 mg/m² and 46-hours 2,400 mg/m² every 2 weeks (LV5FU2), second line, LV5FU2 + oxaliplatin 100 mg/m² as a 2-hour perfusion on day 1 (FOLFOX6), third line, LV5FU2 + irinotecan 180 mg/m² (FOLFIRI)

Experimental arm: first line, FOLFOX6, second line, FOLFIRI, third line, 5-FU 250 mg/m²/day in continuous perfusion 7 out of 8 weeks or capecitabine 2,500 mg/m² per oral 14 out of 21 days or inclusion in a phase I

Inclusion criteria:

• Histologically confirmed metastatic colorectal adenocarcinoma
• Unresectable metastasis
• Bidimensionally measurable disease (WHO criteria)
• WHO performance status of 2 or less
• Adequate hematologic, renal function and liver functions
• No previous chemotherapy other than previous adjuvant chemotherapy or concomitant chemoradiotherapy with 5-fluorouracil and leucovorin for the treatment of the primary tumor completed at least 6 months before inclusion
• Signed written inform consent
• Quality of life questionnaire (QLQ C-30) filled out

Exclusion criteria:

• Pregnant or breast-feeding women
• No possible regular follow-up for psychological, social or geographical reason
• Severe cardiac, respiratory, renal or hepatic failure
• Active coronary heart disease
• Central nervous system metastases
• Past history of second malignancies
• Another investigational drug
• Chronic inflammatory bowel disease
• Previous chemotherapy with irinotecan or oxaliplatin based regimens

Randomization:

Randomization is performed centrally using a minimization technique, stratifying patients according to centre, previous adjuvant treatment, WHO performance status, and number of metastatic sites

Outcomes:

Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up.

Overall survival, secondary surgery, response rate, progression-free survival after the first and the third line of chemotherapy, safety, quality of life and costs

Follow-up:

Tumor assessments is performed every 8 weeks, quality of live assessment every 8 weeks until progression after 2 lines of chemotherapy or for one year if no progression. After the end of the planned treatment, patients are followed up until death or the cut-off date.

Sample size and statistical analyses:

570 patients, 285 per arm will be needed to detect a difference in median of progression-free survival after two lines of chemotherapy of 3 months from 10 months in the control arm to 13 months in the experimental arm, for a type I error of 5% and a power of 80% (bilateral log rank test).

The analysis will be performed according to the intent-to treat principle. An interim analysis is planned after the inclusion of 400 patients with 3 months follow-up or the occurrence of 250 events and reviewed by an independent data monitoring committee.

Estimated duration of the trial: accrual period, 3 years, minimum follow-up, one year

Conditions

Colorectal Cancer; Metastasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

5-fluorouracil

Intervention Type: DRUG

leucovorin

Intervention Type: DRUG

irinotecan

Intervention Type: DRUG

oxaliplatin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed metastatic colorectal adenocarcinoma
• Unresectable metastasis
• Bidimensionally measurable disease (World Health Organization [WHO] criteria)
• WHO performance status of 2 or less
• Adequate hematologic functions (neutrophil count, at least 1500 per cubic millimeter; and platelet count, at least 100,000 per cubic millimetre)
• Adequate renal function (serum creatinine, less than 125 micromol per liter)
• Adequate liver function (bilirubin, not more than 5 times the upper limit of normal)
• No previous chemotherapy other than previous adjuvant chemotherapy or concomitant chemoradiotherapy with 5-fluorouracil and leucovorin for the treatment of the primary tumor completed at least 6 months before inclusion
• Signed written inform consent
• Quality of life questionnaire (QLQ C-30) filled out

Exclusion Criteria

• Pregnant or breast - feeding women
• Impossibility of regular follow-up for psychological, social or geographical reason
• Severe cardiac, respiratory, renal or hepatic failure
• Active coronary heart disease
• Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study
• Central nervous system metastases
• Past history of second malignancies
• Another investigational drug
• Chronic inflammatory bowel disease
• Previous chemotherapy with irinotecan or oxaliplatin based regimens

• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondation Francaise de Cancerologie Digestive

OTHER

Sponsor Role: collaborator

Sanofi

INDUSTRY

Sponsor Role: collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

Sponsor Role: lead

Principal Investigators

Michel Ducreux, Pr

Role: PRINCIPAL_INVESTIGATOR

Gustave Roussy, Cancer Campus, Grand Paris

Jean-Pierre F Pignon, MD, PhD

Role: STUDY_DIRECTOR

Gustave Roussy, Cancer Campus, Grand Paris

Locations

Institut Gustave-Roussy

Villejuif, , France

Countries

France

References

Penichoux J, Michiels S, Bouche O, Etienne PL, Texereau P, Auby D, Rougier P, Ducreux M, Pignon JP; FFCD 2000-05 trial investigators. Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. Eur J Cancer. 2013 May;49(8):1882-8. doi: 10.1016/j.ejca.2013.02.006. Epub 2013 Mar 13.

Reference Type: DERIVED

PMID: 23490654 (View on PubMed)

Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, Rougier P, Gasmi M, Castaing M, Abbas M, Michel P, Gargot D, Azzedine A, Lombard-Bohas C, Geoffroy P, Denis B, Pignon JP, Bedenne L, Bouche O; Federation Francophone de Cancerologie Digestive (FFCD) 2000-05 Collaborative Group. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol. 2011 Oct;12(11):1032-44. doi: 10.1016/S1470-2045(11)70199-1. Epub 2011 Sep 6.

Reference Type: DERIVED

PMID: 21903473 (View on PubMed)

Other Identifiers

CET 815

Identifier Type: -

Identifier Source: secondary_id

FFCD 2000 - 05

Identifier Type: -

Identifier Source: org_study_id